BioCryst Q2: Orladeyo on Track, Navenibart Enrollment Completed; Pipeline De-Risked but Leverage Keeps Rating at Wait

What happened

BioCryst reported Q2 2026 total revenue of $218.3 million with Orladeyo net revenue of $158.2 million, maintaining its full-year Orladeyo guidance of $625–645 million and raising total revenue guidance to $690–715 million. Operating profit reached $98.5 million (GAAP) and $113.2 million non-GAAP, demonstrating strong operating leverage as the company scales. The launch of Orladeyo oral pellets for pediatric patients aged 2–<12 began shipping on August 3, expanding the addressable market. Critically, management confirmed enrollment has been completed in the pivotal ALPHA-ORBIT study of navenibart, removing a key timeline risk for a potential second HAE product. These results reinforce the base-case trajectory of growing cash flows and pipeline progress, though high leverage and single-asset concentration persist as significant risks.

Implication

Investors should view the Q2 results as confirmation that Orladeyo can at least meet the lower end of 2026 guidance, with pediatric pellets providing incremental growth from the second half. The completion of ALPHA-ORBIT enrollment de-risks navenibart’s timeline, though top-line data is not expected until early 2027 and competitive pressures remain. Operating leverage is clear with non-GAAP operating profit of $113 million, yet interest coverage and net debt levels remain elevated, limiting financial flexibility. The raised total revenue guidance hints at contributions beyond Orladeyo, but the equity story still hinges on Orladeyo’s peak sales potential. Consequently, while the margin of safety has improved modestly, the original WAIT rating still applies, with an attractive entry near $5.50 and a trim point around $10.50.

Thesis delta

The original thesis centered on Orladeyo’s cash flow durability and a leveraged bet on navenibart. The completed enrollment in ALPHA-ORBIT partially de-risks that bet, while the Q2 margin and revenue strength support the base case of continued Orladeyo growth. However, as Orladeyo did not exceed the high end of guidance and the capital structure remains stretched, the overall risk-reward has not changed enough to upgrade from WAIT; the rating holds with modestly increased conviction in the pipeline.